Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT

Table 2 ATT-weighted means for transplant groups

	Weighted means			p
Variable	Auto-HSCT	10/10 UD-HSCT	9/10 UD-HSCT	10/10 UD-HSCT vs auto-HSCT	9/10 UD-HSCT vs auto-HSCT
Global population
Median age at transplant, years	47	46	47	0.84	1.00
Median year of transplant	2008	2008	2008	0.66	0.88
Median interval diagnosis transplant (days)	178	179	179	0.80	0.49
Good-risk cytogenetics (%)	33	31	30	1.00	1.00
Poor-risk cytogenetics (%)	15	17	19	1.00	1.00
More than 1 induction to achieve CR1 (%)	16	18	17	0.7	0.91
By cytogenetic risk
Good risk
Median age at transplant, years	44	44	n.a.^a	0.96	n.a.
Median year of transplant	2009	2009	n.a.	0.56	n.a.
Median interval diagnosis transplant (days)	186	188	n.a.	1.00	n.a.
More than 1 induction to achieve CR1 (%)	0.01	0.09	n.a.	0.84	n.a.
Intermediate risk
Patient age (years)	48	48	49	0.96	0.39
Year of transplant	2008	2008	2008	0.36	0.83
Interval diagnosis transplant (days)	174	181	183	0.51	0.90
More than 1 induction to achieve CR1 (%)	19	22	17	0.36	0.91
Intermediate-risk wtFLT3
Patient age (years)	46	48	n.a.	0.75	n.a.
Year of transplant	2008	2009	n.a.	0.46	n.a.
Interval diagnosis transplant (days)	118	115	n.a.	0.93	n.a.
More than 1 induction to achieve CR1 (%)	17	21	n.a.	0.81	n.a.
Poor risk
Patient age (years)	50	50	50	1.00	0.93
Year of transplant	2008	2008	2009	0.87	0.11
Interval diagnosis transplant (days)	172	170	173	1.00	0.91
More than 1 induction to achieve CR1 (%)	24	25	27	0.81	0.77

Legend: ATT average treatment effect among the treated, CR1 first complete remission, wtFLT3 wild-type FLT3
^aIn good risk and intermediate wtFLT3 categories, only auto-HSCT and 10/10 UD-HSCT were analyzed, as the number of 9/10 UD-HSCT transplants resulted too limited

ISSN: 1756-8722